Medical reviewer · menopause nams
Jane Smith, MD, MD, NAMS-certified
Board-certified OB/GYN and NAMS-certified menopause practitioner with 15 years of clinical experience in midlife women's health.
About
Dr. Smith specializes in perimenopause and menopause care, with particular focus on individualized hormone therapy and non-hormonal alternatives.
Education
- MD — (2007)
- Residency in OB/GYN — (2011)
Articles reviewed by Jane Smith, MD
Perimenopause Heart Palpitations: Causes, Patterns, and When to Seek Care
Heart palpitations during perimenopause are common but unsettling. Estrogen fluctuations, autonomic shifts, and overlapping triggers explain most episodes — here is what the research shows and how clinicians evaluate them.
Reviewed: 5/30/2026
HRT After Breast Cancer: Key Considerations for Symptom Management
HRT after breast cancer raises difficult questions for survivors managing menopause symptoms. This guide reviews the current evidence base, non-hormonal alternatives, and frameworks survivors use when discussing care with oncology and menopause clinicians.
Reviewed: 5/30/2026
Menopause Dry Skin and Collagen Loss: Causes, Evidence, Options
Menopause dry skin and collagen loss accelerate sharply in the first five postmenopausal years — women lose roughly 30% of skin collagen. Here's what current evidence shows about why, and which interventions have data.
Reviewed: 5/30/2026
Hair Thinning in Women: Hormonal Causes and Evidence-Based Options
A clinician-reviewed explainer on hormonal hair thinning in women — androgenetic alopecia, menopause shedding, thyroid links, PCOS, telehealth providers, costs, and red flags.
Reviewed: 5/30/2026
Hormonal IUD in Perimenopause: Contraception, Bleeding & HRT Use
A hormonal IUD in perimenopause does three things at once: prevents pregnancy (still possible until 12 months amenorrhea), reduces heavy bleeding by up to 90%, and provides endometrial protection if you add estrogen. Here's what the evidence shows.
Reviewed: 5/30/2026
Hot Flashes Treatment: Evidence-Based Options for Menopause and Night Sweats
A clinician-reviewed look at hot flashes treatment — from hormone therapy and the new neurokinin-3 antagonists to lifestyle changes, telehealth access, and cost. Discuss any approach with a qualified clinician.
Reviewed: 5/30/2026
How to Choose a Menopause Telehealth Provider: An Editorial Buyer's Guide
How to choose menopause telehealth comes down to seven factors: clinician credentials, state coverage, prescribing scope, lab handling, insurance model, communication cadence, and price transparency. This editorial guide walks through each.
Reviewed: 5/30/2026
Compounded vs FDA HRT: Evidence, Safety, and Cost Comparison
Compounded vs FDA HRT differ in regulation, evidence base, dosing accuracy, and out-of-pocket cost. Here is what current guidelines from NAMS, ACOG, and the FDA say — and how telehealth menopause clinics typically prescribe.
Reviewed: 5/30/2026
Estradiol Patch vs Pill: How Transdermal and Oral HRT Compare
Estradiol patch vs pill — transdermal delivery bypasses first-pass liver metabolism and carries a lower venous thromboembolism signal, while oral estradiol is cheaper and well-studied. Here is how the two compare on efficacy, safety, and cost.
Reviewed: 5/30/2026
Estrogen Osteoporosis Prevention: Evidence, Timing, and Bone Health Options
Estrogen withdrawal at menopause triggers rapid bone loss. Here's what the evidence shows about estrogen osteoporosis prevention, the timing hypothesis, alternatives, and how to weigh options with a clinician.
Reviewed: 5/30/2026
Hormonal Migraines in Perimenopause: Causes, Triggers, and Options
Hormonal migraines frequently intensify during perimenopause as estradiol levels swing unpredictably. Here's what current evidence shows about estrogen withdrawal, aura risk, and the options worth discussing with a clinician.
Reviewed: 5/30/2026
HRT Blood Clots Risk: What the Evidence Shows About VTE and Hormone Therapy
The HRT blood clots risk varies sharply by route, formulation, age, and personal history. Transdermal estradiol shows little to no extra venous thromboembolism risk in large database studies, while oral formulations roughly double it from a low baseline.
Reviewed: 5/30/2026